Latest News from NPR

on:

NCPR is supported by:

 
Hourly Newscast
4 min., 45 sec.

Programs

Latest program rundown

Coming up:

Latest Features:
August 20, 2014 | NPR · If you venture away from the protest zone in Ferguson, Mo., there is an idyllic neighborhood, which doesn't have much patience for the out-of-towners who have joined the protests.
 
AP
August 20, 2014 | NPR · President Obama has carefully avoided taking sides following the shooting of Missouri teen Michael Brown, disappointing some African-American observers.
 
August 20, 2014 | NPR · Texas ranks 49th out of 50 states in how much funding it commits to mental health. But San Antonio has become a model for other mental health systems. It has saved $50 million over the past 5 years.
 

Latest program rundown

Coming up:

Latest Features:
EPA/Landov
August 20, 2014 | NPR · Demonstrators want an indictment of the police officer who fatally shot Michael Brown earlier this month. But investigations — one of them a federal civil rights case — can take weeks, if not months.
 
August 20, 2014 | NPR · More than a week now from the police shooting in Ferguson, Mo., it's worth asking: Ideally, what should happen with a police officer stops someone in the street?
 
Courtesy of Mark Pierce
August 20, 2014 | NPR · Enlisting has been a rite of passage for men in the Pierce family since the Civil War. And as America has changed, Mark Pierce and his son Jeremy explain, what it means to serve has, too.
 

Latest Saturday rundown




WE Saturday Feature

AFP/Getty Images
August 16, 2014 | NPR · Both Ukraine and Russia say they're trying to send supplies to residents in eastern Ukraine. But with tensions on both sides running high, that aid may take a while to arrive.
 

Latest Sunday rundown


WE Sunday Feature

August 17, 2014 | NPR · American fighter jets and drones carried out airstrikes against Islamist targets near the Mosul Dam in northern Iraq on Saturday. A breach of the dam could threaten entire cities.
 

Latest program rundown

Coming up:

Avastin

Apr 4, 2012 — U.S. medical practices bought counterfeit medicine labeled as Altuzan from a foreign supplier, the FDA says. Altuzan, which is the Turkish brand name for the blockbuster drug Avastin, is approved for use in Turkey but not in this country.
Comments |
Feb 15, 2012 — Counterfeit versions of diet drugs, Lipitor and a flu medication called Tamiflu have been found in this country before. But so far fake cancer medicines have been rare.
Comments |
Dec 29, 2011 — Avastin slowed the progression of the cancers a bit, but two studies didn't find the drug improved survival overall. Patients getting Avastin as part of treatment with several medicines had more side effects, including blood clots and high blood pressure, than the people who didn't get it.
Comments |
Nov 18, 2011 — After more than a year of deliberations and an unprecedented public hearing in June, the agency has revoked approval of the biotech blockbuster Avastin, a medicine that chokes off the blood supply to various cancer cells, as a treatment for metastatic breast cancer.
Comments |
Oct 13, 2011 — A cancer specialist on an expert panel that voted against keeping Avastin's approval for breast cancer intact explained his decision. He couldn't imagine recommending a drug that only limits progression of cancer without lengthening patient's lives or their quality of life.
Comments |
Jun 30, 2011 — The European Commission gave the OK to an expansion of Avastin's approval to include using the drug in combination with Xeloda, a chemotherapy medicine, to treat metastatic breast cancer.
Comments |
Jun 29, 2011 — Genentech failed to persuade a single member of the Food and Drug Administration's panel of cancer experts that its blockbuster drug Avastin should keep the agency's seal of approval for treating advanced breast cancer.
Comments |
Jun 29, 2011 — In a controversial 2008 decision, the FDA gave fast-track approval for Avastin for breast cancer treatment based on a single study. Now, after subsequent research proved disappointing, a panel has recommended that the agency revoke approval, angering patients and the drugmaker.
Comments |
Apr 29, 2011 — Medicare could save millions if patients with macular degeneration switch to a $50 cancer drug that's just as effective as a $2,000 drug approved for the eye disease. But it was a long haul to get the clinical trial done to prove it.
Comments |
more Avastin from NPR